MNMD
Mind Medicine (MindMed) Inc.NASDAQHealthcareAs of 2026-04-04
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
5.56
P/S
0.00
EV/EBITDA
-10.62
DCF Value
$2.84
FCF Yield
-6.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-84.4%
ROA
-43.7%
ROIC
-44.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-50.4M | $-0.50 |
| FY 2025 | $0.00 | $-183.8M | $-2.06 |
| Q3 2025 | $0.00 | $-67.3M | $-0.78 |
| Q2 2025 | $0.00 | $-42.7M | $-0.50 |
Company Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
2.62
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.